Cardiosense Names John Martin MD, MBA as Chief Medical Officer

Cardiosense has named John Martin, MD, MBA as executive vice president and chief medical officer.

Dr. Martin is a practicing vascular surgeon and seasoned health tech executive. He will lead the company’s clinical development and strategy as it moves through key regulatory milestones and gears up for commercial launch.

He touts executive leadership experience at Butterfly Network, where he helped lead efforts to bring advanced imaging and monitoring solutions into everyday workflows in the hospital, clinics, emergency departments, remote care venues, and at home. He’s also a practicing vascular surgeon at the University of Maryland Vascular Center at Annapolis and the founder of the Heart Health Foundation, a nonprofit focused on education, prevention, and early detection of cardiovascular disease.

Dr. Martin’s appointment follows the recent U.S. Food and Drug Administration (FDA) 510(k) clearance of CardioTag, a significant move toward advanced cardiac function monitoring. Cardiosense expects de novo classification for its first artificial intelligence (AI) algorithm for noninvasive pulmonary capillary wedge pressure (PCWP) estimation in the coming year.

Cardiosense co-founder and CEO Amit Gupta said Dr. Martin’s rare combination of clinical expertise and medtech leadership is exactly what the company needs during this transformative phase.

“As we complete our validation study for our AI algorithm for cardiac filling pressures and advance towards regulatory submission, John’s leadership will accelerate our mission to expand access to personalized, noninvasive hemodynamic-guided care for the millions living with heart failure and other critical conditions,” Gupta told the press.

Dr. Martin said that Cardiosense is building something truly special at the intersection of AI and medicine.

From the operating room to outpatient care, Cardiosense has the potential to transform how we guide therapy, putting actionable, hemodynamic data in the hands of clinicians, and eventually patients, for self-guided care at home,” he said. “As a practicing physician, I’ve seen firsthand how urgently we need better tools for managing volume in heart failure, and we have a line-of-sight to provide value for other conditions such as renal disease, trauma and more. We’re at a can’t-miss junction to open the aperture beyond heart failure and redefine how we manage volume across conditions and settings—noninvasively, affordably, and at scale.”